All In Biotech

Drug Trial Radar · NCT04753697

A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

A Phase 3, Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Subjects With Eosinophilic Esophagitis

Last checked: Nov 19, 2026Latest source record: Mar 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 430 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

430

Actual

Start

Feb 22, 2021

Primary completion

Jan 11, 2024

Study completion Aug 29, 2024

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Feb 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study CC-93538-EE-001 is a Phase 3, multicenter, multinational, randomized, double-blind, placebo-controlled induction and maintenance study to evaluate the efficacy and safety of CC- 93538 in adult and adolescent participants with eosinophilic esophagitis (EoE). The study will incorporate a 24-week Induction Phase followed by a 24-week Maintenance Phase. Participants will be randomized at the beginning of the study into 3 treatment arms: * Placebo for Induction and Maintenance * CC-93538 360 mg Subcutaneous (SC) once weekly for Induction followed by 360 mg SC once every other week for Maintenance * CC-93538 360 mg SC once weekly for Induction and Maintenance

Conditions

  • Eosinophilic Esophagitis

Interventions

  • CC-93538Drug

    Subcutaneous

  • PlaceboOther

    Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Dysphagia Days (DD) at Week 24Time frame: Baseline (Day 1) and Week 24
  2. Percentage of Participants With Peak Esophageal Eosinophil Count <= 6/High-power Field (Hpf) at Week 24Time frame: Week 24

Locations

212 sites in 15 countries. Site status is shown where the registry gives one.

  • Local Institution - 144

    Birmingham, Alabama

  • Local Institution - 158

    Tuscaloosa, Alabama

  • Local Institution - 082

    Phoenix, Arizona

  • Local Institution - 147

    Phoenix, Arizona

  • Local Institution - 041

    Scottsdale, Arizona

  • Local Institution - 029

    Tucson, Arizona

  • Local Institution - 165

    North Little Rock, Arkansas

  • Local Institution - 075

    Lancaster, California

  • Local Institution - 047

    Los Angeles, California

  • Local Institution - 084

    Oakland, California

  • Local Institution - 160

    San Diego, California

  • Local Institution - 068

    Aurora, Colorado

  • Local Institution - 067

    Colorado Springs, Colorado

  • Local Institution - 092

    Denver, Colorado

  • Local Institution - 170

    Littleton, Colorado

  • Local Institution - 128

    Wheat Ridge, Colorado

  • Local Institution - 101

    Bristol, Connecticut

  • Local Institution - 076

    Farmington, Connecticut

  • Local Institution - 156

    Hamden, Connecticut

  • Local Institution - 099

    Clearwater, Florida

  • Local Institution - 036

    Inverness, Florida

  • Local Institution - 042

    Jacksonville, Florida

  • Local Institution - 161

    Miami, Florida

  • Local Institution - 138

    Miami, Florida

  • Local Institution - 110

    North Miami Beach, Florida

  • Local Institution - 146

    Orlando, Florida

  • Local Institution - 088

    Orlando, Florida

  • Local Institution - 133

    Orlando, Florida

  • Local Institution - 169

    Pinellas Park, Florida

  • Local Institution - 168

    Plantation, Florida

  • Local Institution - 037

    Port Orange, Florida

  • Local Institution - 140

    Sweetwater, Florida

  • Local Institution - 043

    Atlanta, Georgia

  • Local Institution - 171

    Atlanta, Georgia

  • Local Institution - 054

    Atlanta, Georgia

  • Local Institution - 117

    Macon, Georgia

  • Local Institution - 024

    Idaho Falls, Idaho

  • Local Institution - 039

    Chicago, Illinois

  • Local Institution - 167

    Gurnee, Illinois

  • Local Institution - 118

    Indianapolis, Indiana

Showing 40 of 212 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.